Alnylam pipeline update: AMVUTTRA catalysts, outlook and profitability
Decision brief
Answer first · skim in under a minute
Alnylam pipeline momentum is anchored by AMVUTTRA’s FDA-approved ATTR-CM and hATTR-PN uses, plus two active Phase 3 catalysts. The update focuses on what changed, what it means for investors, and what to watch next.
This Alnylam pipeline update centers on AMVUTTRA’s dual FDA labels, 2025 profitability after nearly $3 billion in product sales, 2026 net product revenue guidance of $4.9 billion to $5.3 billion, and two active Phase 3 TTR studies that set the next clinical catalysts.
Contents10 sections
Key Takeaways
- AMVUTTRA (vutrisiran) is FDA-labeled for hATTR polyneuropathy and ATTR cardiomyopathy in adults.
- Alnylam said 2025 net product revenues reached nearly $3 billion (+81% YoY) and drove profitability.
- Company 2026 total net product revenue guidance is $4.9 billion to $5.3 billion.
- Phase 3 watch list: NCT07223203 (TRITON-PN) and NCT06679946 (ATTR-CM vutrisiran study).
What does the Alnylam pipeline mean for AMVUTTRA?
AMVUTTRA is now the commercial core of the Alnylam pipeline story. The U.S. label covers adult polyneuropathy of hereditary transthyretin-mediated amyloidosis and adult cardiomyopathy of wild-type or hereditary ATTR amyloidosis.
OpenFDA label text states the cardiomyopathy claim includes reducing cardiovascular death, hospitalizations, and urgent heart failure visits. That dual use is why AMVUTTRA anchors both revenue and franchise strategy.
Label source: openFDA AMVUTTRA label.
How did Alnylam reach profitability?
Alnylam’s 2025 results package, filed with the SEC, credits the ATTR-CM launch for nearly $3 billion in total net product revenues. That figure was about 81% higher than the prior year.
Management framed 2025 as the year commercial scale caught up with the RNAi platform. Profitability followed that sales step-up, not a one-off licensing spike.
Primary filing: Alnylam SEC Exhibit 99.1 (Jan 2026).
2026 revenue guidance and TTR franchise math
For 2026, Alnylam guided combined net product revenues for AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO to $4.9 billion to $5.3 billion. Total TTR (AMVUTTRA and ONPATTRO) sits at $4.4 billion to $4.7 billion in that same package.
- Total net product revenues: $4,900 million to $5,300 million
- Total TTR revenues: $4,400 million to $4,700 million
- Rare products (GIVLAARI, OXLUMO): $500 million to $600 million
Those ranges are company guidance, not third-party consensus. Teams should treat Street models as secondary to the SEC exhibit.
Which Phase 3 catalysts define the next readout window?
Two Phase 3 records on ClinicalTrials.gov are the near-term TTR catalysts tied to this Alnylam pipeline update.
- NCT07223203 (TRITON-PN): nucresiran in hereditary ATTR polyneuropathy; status recruiting; Phase 3.
- NCT06679946: vutrisiran in ATTR cardiomyopathy; status enrolling by invitation; Phase 3.
Nucresiran is the next-generation TTR silencer in the franchise stack. Vutrisiran work extends the AMVUTTRA cardiomyopathy program beyond the initial label.
Pipeline goals beyond TTR in 2026
Alnylam also flagged broader 2026 pipeline goals in the same results materials: multiple clinical readouts, ongoing pivotal studies, Phase 2 starts, and new IND filings. Named second-half 2026 de-risking readouts include ALN-6400 in hereditary hemorrhagic telangiectasia and ALN-HTT02 in Huntington’s disease.
Those programs sit outside the AMVUTTRA cash engine. They matter for long-term growth, not for 2026 product guidance.
What remains unproven for investors and BD teams
Company guidance does not prove Street consensus revenue or EPS figures. Phase 3 status does not prove nucresiran or expanded vutrisiran benefit until data and reviews land.
ATTR-CM competitive share versus other approved agents is not quantified in the SEC exhibit cited here. Do not treat launch narrative as market-share proof.
Related NovaPharma coverage
- AMVUTTRA (vutrisiran) drug profile
- Alnylam Pharmaceuticals company profile
- Cardiff Oncology pipeline update
Frequently Asked Questions
Is AMVUTTRA FDA-approved, and for which uses?
Yes. FDA labeling supports AMVUTTRA for polyneuropathy of hereditary ATTR amyloidosis in adults and for cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults to reduce cardiovascular death, hospitalizations, and urgent heart failure visits.
Did Alnylam reach profitability in 2025?
Yes. In SEC-filed 2025 results commentary, Alnylam tied first-time profitability to nearly $3 billion in total net product revenues, about 81% year-over-year growth, after the U.S. ATTR-CM launch of AMVUTTRA.
Which Alnylam Phase 3 trials should teams watch next?
Watch NCT07223203 (TRITON-PN, nucresiran in hATTR-PN, recruiting) and NCT06679946 (vutrisiran in ATTR cardiomyopathy, enrolling by invitation), both listed as Phase 3 on ClinicalTrials.gov.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for AMVUTTRA.
Unlock full calendar →pharmaand GmbH pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
